Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

M. Lia Palomba, Paola Ghione, Anik R. Patel, Kevin Deighton, Caron Jacobson, Myrna Nahas, A Scott Jung, Anthony J Hatswell, Steve Kanters, Eve Limbrick-Oldfield, Sally W Wade, Julia Thornton Snider, Sattva S. Neelapu, Maria Teresa Riberio, John Gribben, John Radford, Sabela Bobillo, Herve Ghesquieres

Blood (2021) 138 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2021-147608

Published: 2021

Journal Articles

Phosphoglycerate Dehydrogenase Is Required for Germinal Center Formation and Is a Therapeutic Target in MYC- driven Lymphoma

Annalisa D'Avola, Nathalie Legrave, Mylene Tajan, Probir Chakravarty, Ryan Shearer, Hamish King, Eric Cheung, Andrew James Clear, Arief Suryono Gunawan, Lingling Zhang, Louisa James, James MacRae, John Gribben, Dinis Pedro Calado, Karen Vousden, John C. Riches

Blood (2021) 138 (Supplement 1): 717.

https://doi.org/10.1182/blood-2021-150442

Published: 2021

Journal Articles

Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T

Michael J Austin, Leena Halim, Farideh Miraki-Moud, David Taussig, John Bomalaski, John Maher, John Gribben, Peter Szlosarek, Bela Wrench

Blood (2021) 138 (Supplement 1): 2787.

https://doi.org/10.1182/blood-2021-151734

Published: 2021

Journal Articles

Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia

Syed Mian, Celine Philippe, Eleni Maniati, Tiffany Bergot, Marion Piganeau, Doriana Di Bella, Valle Morales, Andrew Finch, Katiuscia Bianchi, Jun Wang, Paolo Gallipoli, Uwe Platzbecker, Daniel H Wiseman, Dominique Bonnet, Delphine Bernard, John Gribben, Kevin Rouault-Pierre

Blood (2021) 138 (Supplement 1): 324.

https://doi.org/10.1182/blood-2021-147726

Published: 2021

Journal Articles

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Blood (2021) 138 (5): 370–381.

https://doi.org/10.1182/blood.2020008743

Published: 2021

Includes: Supplemental data

Journal Articles

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Blood (2017) 130 (Supplement 1): 1750.

https://doi.org/10.1182/blood.V130.Suppl_1.1750.1750

Published: 2017

Journal Articles

Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties

Blood (2017) 130 (Supplement 1): 3273.

https://doi.org/10.1182/blood.V130.Suppl_1.3273.3273

Published: 2017

Journal Articles

Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma

Emma Vilventhraraja, Tetyana Klymenko, PhD, Jennifer Edelmann, MD, John Gribben, Andrejs Ivanov, PhD

Blood (2016) 128 (22): 1763.

https://doi.org/10.1182/blood.V128.22.1763.1763

Published: 2016

Journal Articles

Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups

Jenny Zhang, Anupama Reddy, Cassandra Love, Andrea B. Moffitt, Deepthi Rajagopalan, Sirpa Leppä, Annika Pasanen, MD PhD, Leo Meriranta, MS, Marja-Liisa Karjalainen-Lindsberg, Peter H Norgaard, MD PhD, Mette Pederson, Anne Ortved Gang, Estrid Hogdall, Kristy L. Richards, PhD MD, Yuri D. Fedoriw, MD, Leon Bernal-Mizrachi, MD, Jean L. Koff, MD, Ashley D. Staton, MD, Christopher Flowers, MDMS, Ora Paltiel-Clarfield, Neta Goldschmidt, MD, Maria Calaminici, Andrew James Clear, John Gribben, Evelyn Nguyen, Magdalena Czader, MD PhD, Sarah Lynn Ondrejka, DO, Angela Collie, MD PhD, Eric D Hsi, MD, Rex au-Yeung, Kwong Yok-Lam, Wai Lap Choi, MD, Gopesh Srivastava, Andrew M Evens, DO, MSc, FACP, Monika Pilichowska, MD PhD, Manju Sengar, Nishitha Reddy, MD MSCI, MBBS, Shaoying Li, MD, Elaine S. Jaffe, MD, Tiffany Tzeng, Jyotishka Datta, David Dunson, Sandeep Dave, MD

Blood (2016) 128 (22): 1087.

https://doi.org/10.1182/blood.V128.22.1087.1087

Published: 2016

Journal Articles

Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets

David J Britton, PhD, Edmund Wilkes, BSc, PhD, Pedro Casado, PhD, Vinothini Rajeeve, PhD, Jude Fitzgibbon, John Gribben, Pedro R Cutillas, BSc, PhD

Blood (2016) 128 (22): 5265.

https://doi.org/10.1182/blood.V128.22.5265.5265

Published: 2016

Journal Articles

Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment

Blood (2016) 128 (22): 5199.

https://doi.org/10.1182/blood.V128.22.5199.5199

Published: 2016

Journal Articles

Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors

Pedro Casado, PhD, Edmund Wilkes, PhD, Marym M Hadi, Vinothini Rajeeve, PhD, Farideh Miraki-Moud, PhD, Rebecca Pike, PhD, Ana Del Rio-Machin, PhD, Sameena Iqbal, Jude Fitzgibbon, PhD, John Gribben, Pedro R Cutillas, BSc, PhD

Blood (2016) 128 (22): 840.

https://doi.org/10.1182/blood.V128.22.840.840

Published: 2016

Journal Articles

Alloresponses of Human T-Cells from Adult Peripheral Blood and Umbilical Cord Blood Are Differentially Impacted By Lenalidomide

Caroline Besley, MBBChir, FRCPath, MRCP, Eleni Kotsiou, PhD, Robert Petty, PhD, Sangaralingam Ajanthah, PhD, Claude Chelala, BSc, MSc, DEA, PhD, Essam Ghazaly, PhD, Rifca Le Dieu, MBBS, PhD, Jeff Davies, MBBS, PhD, John Gribben

Blood (2016) 128 (22): 5714.

https://doi.org/10.1182/blood.V128.22.5714.5714

Published: 2016

Journal Articles

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

Jennifer Edelmann, MD, Tetyana Klymenko, PhD, Chen Lu, PhD, Emma Vilventhraraja, Sven Estenfelder, Eugen Tausch, Stephen A Beers, PhD, Stephan Stilgenbauer, Mark S Cragg, PhD, Andrejs Ivanov, PhD, John Gribben

Blood (2016) 128 (22): 971.

https://doi.org/10.1182/blood.V128.22.971.971

Published: 2016

Journal Articles

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Bruce D. Cheson, Marek Trněný, Kamal Bouabdallah, MD, Gregory Dueck, John Gribben, Pieternella J Lugtenburg, MD PhD, Oliver Press, Gilles A. Salles, Günter Fingerle-Rowson, Federico Mattiello, Elisabeth Wassner-Fritsch, Laurie H Sehn

Blood (2016) 128 (22): 615.

https://doi.org/10.1182/blood.V128.22.615.615

Published: 2016

Journal Articles

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Bruce D. Cheson, MD, Peter C Trask, PhD MPH, John Gribben, MDDSc, Natalie Dimier, Eva Kimby, MD PhD, Pieternella J Lugtenburg, MD PhD, Catherine Thieblemont, Elisabeth Wassner Fritsch, MD, Laurie H Sehn, MD MPH

Blood (2015) 126 (23): 1532.

https://doi.org/10.1182/blood.V126.23.1532.1532

Published: 2015

Journal Articles

High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia

Bing Cui, PhD, Liguang Chen, MD PhD, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Jian Yu, PhD, Ling Zhang, PhD, Donna S Neuberg, ScD, William Wierda, MD PhD, Michael Keating, MBBS, Kanti R. Rai, MD, Neil E. Kay, MD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, John Gribben, MDDSc, Thomas J. Kipps, MD, PhD

Blood (2015) 126 (23): 1713.

https://doi.org/10.1182/blood.V126.23.1713.1713

Published: 2015

Journal Articles

Overexpression of HMGB1 Receptor RAGE Is Associated with Worse Clinical Outcome in Patients with Chronic Lymphocytic Leukemia

Faith Norster, MBiochem, Andrew James Clear, BSc, Janet Matthews, Elena Hoxha, MSc, John Gribben, MDDSc, Li Jia, PhD MD

Blood (2015) 126 (23): 617.

https://doi.org/10.1182/blood.V126.23.617.617

Published: 2015

Journal Articles

Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Ian W. Flinn, MD PhD, Mark Brunvand, MD, Michael Y. Choi, MD, Martin J.S. Dyer, Prof., John Gribben, MDDSc, Peter Hillmen, MB, ChB, PhD, Jeffrey Jones, MD MPH, Yan Li, Mehrdad Mobasher, Gregory Vosganian, Thomas J. Kipps, MD, PhD

Blood (2015) 126 (23): 494.

https://doi.org/10.1182/blood.V126.23.494.494

Published: 2015

NARROW

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Phosphoglycerate Dehydrogenase Is Required for Germinal Center Formation and Is a Therapeutic Target in MYC- driven Lymphoma

Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T

Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties

Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma

Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups

Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets

Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment

Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors

Alloresponses of Human T-Cells from Adult Peripheral Blood and Umbilical Cord Blood Are Differentially Impacted By Lenalidomide

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia

Overexpression of HMGB1 Receptor RAGE Is Associated with Worse Clinical Outcome in Patients with Chronic Lymphocytic Leukemia

Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only